Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has been awarded €10.8 million in EU funding under the EIC Accelerator Programme.
Read more here.
Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has been awarded €10.8 million in EU funding under the EIC Accelerator Programme.
Read more here.
![[Hailo in Micro Controller Tips] Embedded platform hosts up to five AI accelerator modules](https://blog.ourcrowd.com/wp-content/themes/Extra/images/post-format-thumb-link.svg)
![[BrightInsight in Forbes] What Biopharma Needs To Know About Investing In SaMD](https://blog.ourcrowd.com/wp-content/themes/Extra/images/post-format-thumb-text.svg)
